Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Ceralasertib in Recurrent Osteosarcoma
NCT04417062Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2020
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, ceralasertib in osteosarcoma (OS), sponsored by Dana-Farber Cancer Institute. Started Nov 2020; status: active, not recruiting.
02
Drugs
olaparibceralasertib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT04417062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04417062.